Autism Spectrum Disorder Pipeline Analysis Report 2026

Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by impairments in social interaction, communication, and repetitive behavioral patterns. According to Alwin Issac et al., 2025, a meta-analysis indicates that approximately 0.77% of children worldwide are diagnosed with ASD. Current therapeutic approaches include behavioral interventions, speech and occupational therapies, and emerging pharmacological candidates targeting associated symptoms. According to the autism spectrum disorder pipeline analysis, increasing research into targeted drug therapies, rising awareness, and advancements in precision medicine are driving pipeline growth. Expanding clinical trials and unmet medical needs are expected to accelerate market development in the coming years.

Report Coverage

The Autism Spectrum Disorder Pipeline Analysis Report gives comprehensive insights into autism spectrum disorder therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for autism spectrum disorder. The autism spectrum disorder report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The autism spectrum disorder pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with autism spectrum disorder treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to autism spectrum disorder.

Autism Spectrum Disorder Pipeline Outlook

Autism spectrum disorder is a neurodevelopmental condition characterized by impaired social interaction, communication difficulties, and repetitive behaviors. It occurs due to complex genetic and environmental factors that affect early brain development, particularly neural connectivity and synaptic function, typically manifesting in early childhood during critical developmental stages.

Autism spectrum disorder treatment involves behavioral therapies, speech and occupational interventions, and medications such as antipsychotics to manage associated symptoms like irritability, anxiety, and aggression, rather than addressing core deficits directly. In December 2025, Astrogen advanced Sperazen (AST-001), a novel autism spectrum disorder drug candidate targeting core symptoms. Clinical trials demonstrated improved social interaction and communication, with long-term safety in pediatric patients. The therapy aims to address early neurodevelopmental deficits during the critical treatment window.

Autism Spectrum Disorder Epidemiology

The pipeline is increasingly influenced by evolving epidemiological trends and unmet clinical needs. As per Alwin Issac et al., 2025, a meta-analysis of 66 studies covering over 21 million children reported a global ASD prevalence of 0.77%, with higher incidence in boys at 1.14%. According to the study, regional distribution included 25 studies in Europe, 22 in Asia, 13 in America, and 3 each in Africa and Australia, with Australia showing the highest prevalence. These trends support targeted pipeline expansion and region-specific therapeutic development strategies.

Autism Spectrum Disorder - Pipeline Therapeutic Assessment

This section of the report covers the analysis of autism spectrum disorder drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The autism spectrum disorder pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• Peptides
• Polymers

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Autism Spectrum Disorder Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II with approximately 58%, covers a major share of the total autism spectrum disorder clinical trials, reflecting strong mid-stage clinical validation and accelerating therapeutic innovation. Phase I holds nearly 19%, indicating a robust influx of early-stage candidates. Phase III accounts for about 16%, supporting near-commercial opportunities.

Autism Spectrum Disorder Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the autism spectrum disorder pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The autism spectrum disorder report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for autism spectrum disorder. Catecholamine-modulating therapies are emerging as promising approaches for autism spectrum disorder. For instance, L1-79, a tyrosine hydroxylase inhibitor, is under clinical evaluation for targeting core social deficits. It works by regulating catecholamine synthesis, thereby improving social interaction and communication. This approach focuses on addressing underlying neurobiological pathways rather than only managing associated symptoms.

Autism Spectrum Disorder Clinical Trials - Key Players

The report for the autism spectrum disorder pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed autism spectrum disorder therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in autism spectrum disorder clinical trials:

• Fenix Innovation Group
• MapLight Therapeutics
• Neuroventi Inc.
• Neurotech International Limited
• Definium Therapeutics US, Inc.
• Kuzani Pharmaceuticals, Inc.
• Bazelet Nehushtan Ltd.
• ACADIA Pharmaceuticals Inc.
• Montera Health Texas LLC
• Intra-Cellular Therapies, Inc.
• Bristol-Myers Squibb
• Vanda Pharmaceuticals

Autism Spectrum Disorder - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for autism spectrum disorder. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of autism spectrum disorder drug candidates.

Drug: NTI164

NTI164 is a full-spectrum medicinal cannabis plant extract being developed by Fenix Innovation Group for autism spectrum disorder. This Phase III HarmonyPlus study is evaluating the efficacy and safety of daily oral administration over 16 weeks, focusing on core and associated ASD symptoms. The drug is modulating immune dysregulation and neuroinflammatory pathways, supported by genomic and proteomic findings, while demonstrating rapid absorption and sustained plasma levels. The randomized, double-blind, placebo-controlled trial is enrolling pediatric and young adult patients, with primary completion expected by July 2029 and full study completion by July 2030.

Drug: ML-004

ML-004 is being evaluated by MapLight Therapeutics in a Phase 2 open-label extension study assessing its long-term safety and tolerability in adolescents and adults with autism spectrum disorder (ASD). The drug is being administered as immediate-release and extended-release oral tablets, targeting the 5-HT1B receptor to modulate neural circuits associated with social behavior. The study is enrolling approximately 120 participants who have completed a prior trial, with completion expected by December 2027. Researchers are examining sustained safety outcomes while further exploring its potential to improve social interaction and behavioral responses.

Drug: NV01-A02

NV01-A02 is being evaluated in a Phase II clinical trial sponsored by Neuroventi Inc., focusing on children with autism spectrum disorder. The study is examining the drug’s efficacy and safety through a randomized, double-blind, placebo-controlled design. NV01-A02 is a novel, orally administered, single-molecule therapy that modulates multiple neuroreceptors, including dopamine and serotonin, to improve social interaction. The trial is currently recruiting and is expected to reach primary completion by September 2025, with overall completion anticipated by December 2026.

Key Questions Answered in the Autism Spectrum Disorder Pipeline Insight Report

• Which companies/institutions are leading autism spectrum disorder drug development?
• Which company is leading the autism spectrum disorder pipeline development activities?
• What is the current autism spectrum disorder commercial assessment?
• What are the opportunities and challenges present in the autism spectrum disorder pipeline landscape?
• What is the efficacy and safety profile of autism spectrum disorder pipeline drugs?
• Which company is conducting major trials for autism spectrum disorder drugs?
• Which companies/institutions are involved in autism spectrum disorder collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in autism spectrum disorder?

Reasons To Buy This Report

The Autism Spectrum Disorder Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for autism spectrum disorder. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into autism spectrum disorder collaborations, regulatory environments, and potential growth opportunities.